4-[5-methyl-6-(2-methyl-pyridin-3-yloxy)-pyrimidin-4-yloxy]-piperidine-1-carboxylic acid isopropyl ester | 930093-71-3

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-[5-methyl-6-(2-methyl-pyridin-3-yloxy)-pyrimidin-4-yloxy]-piperidine-1-carboxylic acid isopropyl ester
• 英文别名: Isopropyl 4-(5-methyl-6-(2-methylpyridin-3-yloxy)pyrimidin-4-yloxy)piperidine-1-carboxylate；propan-2-yl 4-[5-methyl-6-(2-methylpyridin-3-yl)oxypyrimidin-4-yl]oxypiperidine-1-carboxylate
• CAS: 930093-71-3
• 化学式: C₂₀H₂₆N₄O₄
• 分子量: 386.451
• InChiKey: YHKUMVXEUWUPKX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  28
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  86.7
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  4,6-二氯-5-甲基嘧啶 在 potassium tert-butylate 、 potassium carbonate 作用下， 以 四氢呋喃 、 二甲基亚砜 为溶剂， 生成 4-[5-methyl-6-(2-methyl-pyridin-3-yloxy)-pyrimidin-4-yloxy]-piperidine-1-carboxylic acid isopropyl ester
  参考文献：
  名称：

  Discovery of a second generation agonist of the orphan G-protein coupled receptor GPR119 with an improved profile

  摘要：

  The design and synthesis of a second generation GPR119-agonist clinical candidate for the treatment of diabetes is described. Compound 16 (APD597, JNJ-38431055) was selected for preclinical development based on a good balance between agonist potency, intrinsic activity and in particular on its good solubility and reduced drug-drug interaction potential. In addition, extensive in vivo studies showed a more favorable metabolic profile that may avoid the generation of long lasting metabolites with the potential to accumulate in clinical studies. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.12.092

文献信息

• Modulators of Metabolism and the Treatment of Disorders Related Thereto
  申请人：Jones Robert M.

  公开号：US20100160359A1

  公开（公告）日：2010-06-24

  The present invention relates to 4-[5-methyl-6-(2-methyl-pyridin-3-yloxy)-pyrimidin-4-yloxy]-piperidine-1-carboxylic acid isopropyl ester, pharmaceutically acceptable salts, solvates and hydrates thereof that are modulators of glucose metabolism. Accordingly, compounds of the present invention are useful in the treatment of metabolic-related disorders and complications thereof, such as, diabetes and obesity.

  本发明涉及4-[5-甲基-6-(2-甲基吡啶-3-氧基)-嘧啶-4-氧基]-哌啶-1-羧酸异丙酯，其药学上可接受的盐、溶剂和水合物，它们是葡萄糖代谢调节剂。因此，本发明的化合物在代谢相关疾病和并发症的治疗中是有用的，例如糖尿病和肥胖症。
• MODULATORS OF METABOLISM AND THE TREATMENT OF DISORDERS RELATED THERETO
  申请人：Arena Pharmaceuticals, Inc.

  公开号：EP1931654B1

  公开（公告）日：2009-04-22
• COMBINATION THERAPY FOR THE TREATMENT OF DIABETES AND RELATED CONDITIONS
  申请人：Boehringer Ingelheim International GmbH

  公开号：EP2344195A2

  公开（公告）日：2011-07-20
• COMBINATION OF A GPR119 AGONIST AND THE DPP-IV INHIBITOR LINAGLIPTIN FOR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS
  申请人：Boehringer Ingelheim International GmbH

  公开号：EP2547339A1

  公开（公告）日：2013-01-23
• Combination therapy for the treatment of diabetes and related conditions
  申请人：Mark Michael

  公开号：US20110263617A1

  公开（公告）日：2011-10-27

  The present invention relates to combinations of DPP-4 inhibitors with GPR119 agonists, as well as to the use of these combinations for treating and/or preventing metabolic diseases, particularly diabetes (especially type 2 diabetes mellitus) and conditions related thereto.